Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.66 USD
-0.14 (-7.78%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $1.65 -0.01 (-0.60%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RGLS 1.66 -0.14(-7.78%)
Will RGLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RGLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGLS
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
RGLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
Other News for RGLS
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Buy Rating Affirmed on Regulus Amid Promising ADPKD Trial Updates
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Regulus price target raised by $17 at Canaccord, here's why